At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 47 enrolled
Drug / intervention
bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating bimekizumab and Placebo for Moderate to Severe Plaque Psoriasis. Completed, enrolled 47 participants across 9 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque Psoriasis
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartSep 2021
Primary CompletionSep 2022
Study CompletionSep 2022
TodayJul 2026
First PostedAug 25, 2021
Enrollment StartSep 27, 2021
Primary CompletionSep 5, 2022
Study CompletionSep 6, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.9 years ago
Interventions
bimekizumabdrug
Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
Placeboother
Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.